🇺🇸 FDA
Patent

US 8569351

Dual-acting benzyl triazole antihypertensive agents having angiotensin II type receptor antagonist activity and neprilysin-inhibition activity

granted A61KA61K31/415A61K31/4164

Quick answer

US patent 8569351 (Dual-acting benzyl triazole antihypertensive agents having angiotensin II type receptor antagonist activity and neprilysin-inhibition activity) held by Theravance, Inc. expires Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Oct 29 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K31/415, A61K31/4164, A61K31/417, A61K31/4188